Scarica l'app Stockscreener
17.76
6.35%
1.06
Dopo l'orario di chiusura:
18.11
0.35
+1.97%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AVTX Giù?
Forum
Previsione
Frazionamento azionario
Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie
Avalo Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
AVTX Technical Analysis & Stock Price Forecast - Intellectia AI
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Sell Alert: Christopher Sullivan Sells Shares of Avalo T - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $133,807.83 in Stock - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 7,980 Shares - MarketBeat
Avalo Therapeutics CFO Sullivan sells $270k in stock - Investing.com
Avalo Therapeutics (AVTX) CMO Doyle Mittie sells $10,864 in stock - Investing.com
Avalo Therapeutics (AVTX) CFO executes Rule 10b5-1 stock sale plan - Stock Titan
Avalo Therapeutics (AVTX) CMO exercises options, sells 679 pre-planned shares - Stock Titan
Wall Street experts anticipate Avalo Therapeutics (AVTX) could surge by 113.34%: Key Insights You Need to Know - Bitget
Avalo Therapeutics, Inc. (AVTX) stock price, news, quote and history - Yahoo Finance Singapore
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know - Yahoo Finance
[144] Avalo Therapeutics, Inc. SEC Filing - Stock Titan
Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,339 options - Stock Titan
Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,370 vested options - Stock Titan
Logos Global (AVTX) discloses 1,285,000-share position, including options - Stock Titan
AVTX SEC FilingsAvalo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Avalo Therapeutics (AVTX) director acquires 3,166 shares via RSU vesting - Stock Titan
Avalo Therapeutics (AVTX) director exercises 3,166 RSUs, holds 6,333 shares - Stock Titan
Director at Avalo Therapeutics (AVTX) converts 3,166 RSUs to stock - Stock Titan
Avalo Therapeutics (AVTX) CEO exercises RSUs, shares withheld for taxes - Stock Titan
Avalo Therapeutics (AVTX) CFO nets shares from RSU vesting and tax settlement - Stock Titan
Director at Avalo Therapeutics (AVTX) exercises 3,166 RSUs into common stock - Stock Titan
Director at Avalo Therapeutics (AVTX) gains 3,166 common shares - Stock Titan
Growth Recap: Can Avalo Therapeutics Inc grow without external fundingMarket Performance Report & Safe Entry Point Identification - baoquankhu1.vn
US Stocks Recap: Can Avalo Therapeutics Inc outperform under higher oil pricesMarket Sentiment Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Upgraded to “Hold” at Wall Street Zen - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Volatility Watch: What analysts say about Avalo Therapeutics Inc stock2026 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
HC Wainwright Has Positive Outlook for AVTX Q1 Earnings - Defense World
Avalo Therapeutics' Jonathan Goldman and Mitchell Chan to Not Stand for Re-election - TradingView
Two Avalo Therapeutics (AVTX) directors to step down after 2026 meeting - stocktitan.net
Avalo Therapeutics, Inc. Announces Departure of Directors Dr. Jonathan Goldman and Mitchell Chan - marketscreener.com
HC Wainwright Issues Positive Outlook for AVTX Earnings - MarketBeat
Aug Macro: Is Avalo Therapeutics Inc a potential multi bagger2026 Sector Moves & Intraday High Probability Setup Alerts - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $40.00 at HC Wainwright - Defense World
What date does Avalo Therapeutics's (AVTX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysis Recap: Is Avalo Therapeutics Inc in a bullish channel2026 Setups & Momentum Based Trading Ideas - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Avalo Therapeutics price target to $40 on trial confidence - au.investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
AVTX: HC Wainwright Raises Price Target, Maintains Buy Rating | - GuruFocus
H.C. Wainwright Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Avalo Therapeutics 2025 Financial Review - AlphaStreet
Is Avalo Therapeutics Inc a potential multi bagger2026 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX St - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from BTIG Research - MarketBeat
Mizuho Securities Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Avalo Therapeutics Reports 2025 Financial Results and Prepares for Key Phase 2 LOTUS Trial Data of AVTX-009 in Hidradenitis Suppurativa - minichart.com.sg
BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Avalo Therapeutics stock maintains Buy rating at BTIG ahead of trial By Investing.com - Investing.com South Africa
Avalo Therapeutics stock maintains Buy rating at BTIG ahead of trial - Investing.com India
Key facts: Avalo Therapeutics posts $78.3M 2025 loss; Q4 EPS -$1.13 - TradingView
Guggenheim reiterates Buy rating on Avalo Therapeutics stock By Investing.com - Investing.com Australia
Guggenheim reiterates Buy rating on Avalo Therapeutics stock - Investing.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):